PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1725148
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1725148
Urokinase Market Forecasts to 2032 - Global Analysis By Type (Urokinase Powder and Urokinase Solution), Source, Route of Administration, Application, End User and By Geography
According to Stratistics MRC, the Global Urokinase Market is accounted for $2.08 billion in 2025 and is expected to reach $3.50 billion by 2032 growing at a CAGR of 7.7% during the forecast period. Urokinase is a thrombolytic enzyme used medically to dissolve blood clots in the body. It is a serine protease originally derived from human urine, but now commonly produced using recombinant DNA technology. Urokinase works by converting plasminogen to plasmin, an enzyme that breaks down fibrin, the primary protein component of blood clots. It is primarily used to treat conditions such as pulmonary embolism, deep vein thrombosis, and catheter blockages. As a fibrinolytic agent, urokinase plays a vital role in restoring blood flow in occluded vessels, making it a critical therapeutic option in emergency and interventional medicine.
According to 2024 article by British Heart Foundation, 7.6 million people are living in with heart and circulatory disease in UK.
Market Dynamics:
Driver:
Rising Prevalence of Thrombotic Disorders
The growing incidence of thrombotic disorders is propelling the urokinase market due to the heightened need for thrombolytic treatments. The enzyme urokinase, which is employed to break down blood clots, plays a vital role in the treatment of conditions like pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. As the global prevalence of these disorders rises, particularly among aging populations, the demand for effective clot-dissolving treatments is increasing. This trend is benefiting the urokinase market and spurring further developments in its production and application.
Restraint:
High Treatment Costs
High treatment costs significantly hinder the growth of the urokinase market by limiting accessibility for patients and healthcare providers, particularly in low- and middle-income regions. These elevated expenses reduce the adoption of urokinase-based therapies, as more affordable alternatives are sought. Additionally, high costs strain healthcare budgets, discourage insurance coverage, and restrict widespread clinical use, ultimately slowing market expansion and impeding innovation in thrombolytic treatments.
Opportunity:
Technological Advancements in Drug Delivery
Technological advancements in drug delivery systems have significantly impacted the Urokinase market by enhancing its therapeutic efficacy and precision. Innovations such as targeted delivery mechanisms and nanoparticle-based formulations ensure better bioavailability and reduced side effects. These advancements improve the drug's ability to target specific sites, optimizing the treatment of conditions like blood clots and heart attacks. Additionally, controlled release technologies and personalized drug delivery systems contribute to improved patient outcomes, driving demand and growth within the Urokinase market.
Threat:
Risk of Bleeding Complications
The risk of bleeding complications significantly hinders the growth of the urokinase market. Urokinase, a thrombolytic agent, carries a high potential for causing internal bleeding, particularly in patients with underlying conditions or on anticoagulants. This safety concern limits its widespread adoption among healthcare providers, prompting cautious prescription practices. Additionally, regulatory restrictions and the availability of safer alternatives further restrain market expansion, negatively impacting demand and overall market performance.
Covid-19 Impact
The COVID-19 pandemic significantly disrupted the urokinase market due to delays in elective surgeries, reduced hospital admissions, and supply chain interruptions. Demand for non-COVID-related therapies, including thrombolytic agents like urokinase, declined during the peak of the pandemic. However, as healthcare systems stabilized and surgical procedures resumed, the market began recovering. Additionally, increased awareness of thrombotic complications in COVID-19 patients indirectly supported demand for anticoagulant and thrombolytic therapies.
The urokinase solution segment is expected to be the largest during the forecast period
The urokinase solution segment is expected to account for the largest market share during the forecast period because Urokinase solutions, particularly in intravenous and local delivery forms, are gaining preference due to their ability to rapidly dissolve blood clots, improving patient outcomes in conditions like pulmonary embolism and deep vein thrombosis. The growing adoption of urokinase solutions in hospitals and healthcare facilities, combined with ongoing research, is further fueling the segment's positive impact on market expansion.
The deep vein thrombosis segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the deep vein thrombosis segment is predicted to witness the highest growth rate, due to the rising incidence of thrombotic disorders and increased awareness of early diagnosis and treatment. Urokinase, a thrombolytic agent, is widely used to dissolve blood clots in DVT patients, leading to its growing demand. Advancements in healthcare infrastructure and an aging population further contribute to market expansion. This trend positions DVT as a key driver fueling sustained growth and innovation in the urokinase market.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising cardiovascular cases, increased awareness, and improved access to advanced therapies are driving demand. This growth is fostering innovation, encouraging investments, and improving patient outcomes across developing nations. Additionally, government support and expanding healthcare infrastructure are accelerating market penetration, making life-saving thrombolytic therapies more accessible, ultimately contributing to better public health and a stronger regional pharmaceutical landscape.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to increasing awareness of thrombolytic therapies. Advancements in healthcare infrastructure, strong presence of key pharmaceutical players, and supportive regulatory frameworks further fuel market expansion. The growing geriatric population and demand for minimally invasive procedures enhance the uptake of urokinase-based treatments. Collectively, these factors are significantly improving patient outcomes and driving the regional market's growth and innovation.
Key players in the market
Some of the key players profiled in the Urokinase Market include Syner-Med Ltd., Microbix Biosystems Inc., Wuxi Green Pharmaceutical Co., Ltd., Jiangxi Haoran Bio-Pharma Co., Ltd., Medicure Inc., Lee's Pharmaceutical Holdings Ltd., Taj Pharmaceuticals Limited, Jiangsu Techpool Bio-Pharma Co., Ltd., Guangzhou Recomgen Biotech Co., Ltd., LGM Pharma, ScienCell Research Laboratories, Inc., BioVision, Inc., Abbott Laboratories, Enzo Life Sciences, Inc., Molecular Innovations, Inc., Prospec-Tany Technogene Ltd., Wuhan YZY Biopharma Co., Ltd., GenScript Biotech Corporation and Chymotech AS.
Key Developments:
In August 2024, Abbott and Medtronic announced a significant global partnership, to integrate Abbott's FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aims to enhance diabetes management by enabling automatic insulin adjustments based on real-time glucose data.
In June 2024, Abbott has partnered with the National Association of Community Health Centers (NACHC) to improve access to nutritious food and health services. The collaboration aims to enhance healthcare delivery and address the growing health challenges related to nutrition in underserved communities.
Types Covered:
- Urokinase Powder
- Urokinase Solution
Sources Covered:
- Human-derived Urokinase
- Recombinant Urokinase
Routes of Administration Covered:
- Intravenous
- Intracatheter
Applications Covered:
- Pulmonary Embolism
- Deep Vein Thrombosis
- Catheter Occlusion
- Myocardial Infarction
- Other Application
End Users Covered:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Urokinase Market, By Type
- 5.1 Introduction
- 5.2 Urokinase Powder
- 5.3 Urokinase Solution
6 Global Urokinase Market, By Source
- 6.1 Introduction
- 6.2 Human-derived Urokinase
- 6.3 Recombinant Urokinase
7 Global Urokinase Market, By Route of Administration
- 7.1 Introduction
- 7.2 Intravenous
- 7.3 Intracatheter
8 Global Urokinase Market, By Application
- 8.1 Introduction
- 8.2 Pulmonary Embolism
- 8.3 Deep Vein Thrombosis
- 8.4 Catheter Occlusion
- 8.5 Myocardial Infarction
- 8.6 Other Application
9 Global Urokinase Market, By End User
- 9.1 Introduction
- 9.2 Hospitals
- 9.3 Specialty Clinics
- 9.4 Ambulatory Surgical Centers
- 9.5 Other End Users
10 Global Urokinase Market, By Geography
- 10.1 Introduction
- 10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
- 10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
- 10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa
11 Key Developments
- 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 11.2 Acquisitions & Mergers
- 11.3 New Product Launch
- 11.4 Expansions
- 11.5 Other Key Strategies
12 Company Profiling
- 12.1 Syner-Med Ltd.
- 12.2 Microbix Biosystems Inc.
- 12.3 Wuxi Green Pharmaceutical Co., Ltd.
- 12.4 Jiangxi Haoran Bio-Pharma Co., Ltd.
- 12.5 Medicure Inc.
- 12.6 Lee's Pharmaceutical Holdings Ltd.
- 12.7 Taj Pharmaceuticals Limited
- 12.8 Jiangsu Techpool Bio-Pharma Co., Ltd.
- 12.9 Guangzhou Recomgen Biotech Co., Ltd.
- 12.10 LGM Pharma
- 12.11 ScienCell Research Laboratories, Inc.
- 12.12 BioVision, Inc.
- 12.13 Abbott Laboratories
- 12.14 Enzo Life Sciences, Inc.
- 12.15 Molecular Innovations, Inc.
- 12.16 Prospec-Tany Technogene Ltd.
- 12.17 Wuhan YZY Biopharma Co., Ltd.
- 12.18 GenScript Biotech Corporation
- 12.19 Chymotech AS
List of Tables
- Table 1 Global Urokinase Market Outlook, By Region (2024-2032) ($MN)
- Table 2 Global Urokinase Market Outlook, By Type (2024-2032) ($MN)
- Table 3 Global Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
- Table 4 Global Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
- Table 5 Global Urokinase Market Outlook, By Source (2024-2032) ($MN)
- Table 6 Global Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
- Table 7 Global Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
- Table 8 Global Urokinase Market Outlook, By Administration (2024-2032) ($MN)
- Table 9 Global Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
- Table 10 Global Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
- Table 11 Global Urokinase Market Outlook, By Application (2024-2032) ($MN)
- Table 12 Global Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
- Table 13 Global Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
- Table 14 Global Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
- Table 15 Global Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
- Table 16 Global Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
- Table 17 Global Urokinase Market Outlook, By End User (2024-2032) ($MN)
- Table 18 Global Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
- Table 19 Global Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
- Table 20 Global Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
- Table 21 Global Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
- Table 22 North America Urokinase Market Outlook, By Country (2024-2032) ($MN)
- Table 23 North America Urokinase Market Outlook, By Type (2024-2032) ($MN)
- Table 24 North America Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
- Table 25 North America Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
- Table 26 North America Urokinase Market Outlook, By Source (2024-2032) ($MN)
- Table 27 North America Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
- Table 28 North America Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
- Table 29 North America Urokinase Market Outlook, By Administration (2024-2032) ($MN)
- Table 30 North America Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
- Table 31 North America Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
- Table 32 North America Urokinase Market Outlook, By Application (2024-2032) ($MN)
- Table 33 North America Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
- Table 34 North America Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
- Table 35 North America Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
- Table 36 North America Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
- Table 37 North America Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
- Table 38 North America Urokinase Market Outlook, By End User (2024-2032) ($MN)
- Table 39 North America Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
- Table 40 North America Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
- Table 41 North America Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
- Table 42 North America Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
- Table 43 Europe Urokinase Market Outlook, By Country (2024-2032) ($MN)
- Table 44 Europe Urokinase Market Outlook, By Type (2024-2032) ($MN)
- Table 45 Europe Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
- Table 46 Europe Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
- Table 47 Europe Urokinase Market Outlook, By Source (2024-2032) ($MN)
- Table 48 Europe Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
- Table 49 Europe Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
- Table 50 Europe Urokinase Market Outlook, By Administration (2024-2032) ($MN)
- Table 51 Europe Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
- Table 52 Europe Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
- Table 53 Europe Urokinase Market Outlook, By Application (2024-2032) ($MN)
- Table 54 Europe Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
- Table 55 Europe Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
- Table 56 Europe Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
- Table 57 Europe Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
- Table 58 Europe Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
- Table 59 Europe Urokinase Market Outlook, By End User (2024-2032) ($MN)
- Table 60 Europe Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
- Table 61 Europe Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
- Table 62 Europe Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
- Table 63 Europe Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
- Table 64 Asia Pacific Urokinase Market Outlook, By Country (2024-2032) ($MN)
- Table 65 Asia Pacific Urokinase Market Outlook, By Type (2024-2032) ($MN)
- Table 66 Asia Pacific Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
- Table 67 Asia Pacific Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
- Table 68 Asia Pacific Urokinase Market Outlook, By Source (2024-2032) ($MN)
- Table 69 Asia Pacific Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
- Table 70 Asia Pacific Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
- Table 71 Asia Pacific Urokinase Market Outlook, By Administration (2024-2032) ($MN)
- Table 72 Asia Pacific Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
- Table 73 Asia Pacific Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
- Table 74 Asia Pacific Urokinase Market Outlook, By Application (2024-2032) ($MN)
- Table 75 Asia Pacific Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
- Table 76 Asia Pacific Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
- Table 77 Asia Pacific Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
- Table 78 Asia Pacific Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
- Table 79 Asia Pacific Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
- Table 80 Asia Pacific Urokinase Market Outlook, By End User (2024-2032) ($MN)
- Table 81 Asia Pacific Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
- Table 82 Asia Pacific Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
- Table 83 Asia Pacific Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
- Table 84 Asia Pacific Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
- Table 85 South America Urokinase Market Outlook, By Country (2024-2032) ($MN)
- Table 86 South America Urokinase Market Outlook, By Type (2024-2032) ($MN)
- Table 87 South America Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
- Table 88 South America Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
- Table 89 South America Urokinase Market Outlook, By Source (2024-2032) ($MN)
- Table 90 South America Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
- Table 91 South America Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
- Table 92 South America Urokinase Market Outlook, By Administration (2024-2032) ($MN)
- Table 93 South America Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
- Table 94 South America Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
- Table 95 South America Urokinase Market Outlook, By Application (2024-2032) ($MN)
- Table 96 South America Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
- Table 97 South America Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
- Table 98 South America Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
- Table 99 South America Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
- Table 100 South America Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
- Table 101 South America Urokinase Market Outlook, By End User (2024-2032) ($MN)
- Table 102 South America Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
- Table 103 South America Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
- Table 104 South America Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
- Table 105 South America Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
- Table 106 Middle East & Africa Urokinase Market Outlook, By Country (2024-2032) ($MN)
- Table 107 Middle East & Africa Urokinase Market Outlook, By Type (2024-2032) ($MN)
- Table 108 Middle East & Africa Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
- Table 109 Middle East & Africa Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
- Table 110 Middle East & Africa Urokinase Market Outlook, By Source (2024-2032) ($MN)
- Table 111 Middle East & Africa Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
- Table 112 Middle East & Africa Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
- Table 113 Middle East & Africa Urokinase Market Outlook, By Administration (2024-2032) ($MN)
- Table 114 Middle East & Africa Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
- Table 115 Middle East & Africa Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
- Table 116 Middle East & Africa Urokinase Market Outlook, By Application (2024-2032) ($MN)
- Table 117 Middle East & Africa Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
- Table 118 Middle East & Africa Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
- Table 119 Middle East & Africa Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
- Table 120 Middle East & Africa Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
- Table 121 Middle East & Africa Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
- Table 122 Middle East & Africa Urokinase Market Outlook, By End User (2024-2032) ($MN)
- Table 123 Middle East & Africa Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
- Table 124 Middle East & Africa Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
- Table 125 Middle East & Africa Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
- Table 126 Middle East & Africa Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
